Generic Ozempic can be made in Canada as of next week. Will it be ...
As of Dec. 29, Health Canada had received nine submissions seeking approval to make semaglutide, the active ingredient in Ozempic and Wegovy.
globalnews.caHere are the latest widely reported developments on Ozempic generics in Canada:
-
Health Canada approved the first generic version of Ozempic (semaglutide) on April 28, 2026. The approval covered a generic semaglutide injectable from Dr. Reddy's Laboratories, confirming safety, efficacy, and quality as meeting regulatory standards. This marks the first time a generic semaglutide product has clearance in Canada.[1]
-
Prior to full approvals, Canada began permitting generic production as of late December 2025, with several companies (including Sz Canada Apot, Te Canada, Taro Pharmaceuticals, Aspen Pharmacare Canada, and others) applying for authorization to manufacture semaglutide. Industry observers noted that regulatory timelines suggested availability in early to mid-2026 rather than January 2026, due to the complexity of generics and the need for Health Canada reviews.[2][3][4]
-
Several outlets highlighted that even once generics are approved, actual patient access may lag by months. Reasons include manufacturing capacity, distribution, pharmacy stocking, and negotiated pricing. Industry experts and company statements emphasized ongoing support for patients using semaglutide (Ozempic and Wegovy) during this transition, including potential financial and savings assistance for insured and uninsured patients.[3][4]
-
Canadian media coverage throughout early 2026 framed this as a pivotal moment for diabetes and weight-management treatment access in the country, with expectations of price competition potentially reducing out-of-pocket costs for many patients in the longer term, while regulators continued to monitor safety and bioequivalence closely.[4][7][3]
-
Context from prior reporting indicated that Canada was notable for allowing generic semaglutide development sooner than many other markets, because patent expiry and regulatory exclusivity signals allowed substitution after regulatory clearance. Analysts anticipated a multi-month path from submission to pharmacy availability, followed by a period of price competition and new payer arrangements.[8][2][4]
If you’d like, I can pull more recent updates or summarize price expectations and payer coverage in your province or region. I can also look up Montana or New Jersey-specific guidance if you’re considering cross-border options. Please tell me which specifics you’d like.